Skip to content

Debt-to-equity at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
0.1×0.0×
Biogen logo
BiogenBIIB
0.4×+0.1×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
0.1×-0.1×
Insmed logo
InsmedINSM
0.8×-10.7×
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
0.2×+0.2×
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
0.3×-0.8×

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation

See full
Market cap$910.66M+145%
Enterprise value$634.23M+244%
P/S112.5×-10.3×

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Current ratio13.1×+2.2×

Where this comes from

Calculated from Solid Biosciences Inc.’s reported figures.

Based on the most recent quarter.

The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Solid Biosciences Inc.'s debt-to-equity?
Solid Biosciences Inc. (SLDB) reported debt-to-equity of 0.1× in Q1 2026.
How has Solid Biosciences Inc.'s debt-to-equity changed year-over-year?
Solid Biosciences Inc.'s debt-to-equity decreased by 31.2% year-over-year, from 0.1× to 0.1×.
What is the long-term trend for Solid Biosciences Inc.'s debt-to-equity?
Over 5 years (2020 to 2025), Solid Biosciences Inc.'s debt-to-equity has grown at a 23.7% compound annual growth rate (CAGR), from 0× to 0.1×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.